The U.S. Food and Drug Administration (FDA) has cleared for marketing what it is calling the first blood test for diagnosing Alzheimer’s disease. The test from Fujirebio Diagnostics, Inc. and branded as “Lumipulse” was found to reliably predict the presence or absence of amyloid pathology associated with Alzheimer’s disease during a study with 499 patients, […]